We are currently in the process of performing deep targeted-sequencing of the same cfDNA libraries achieved in the present analysis, which would permit the detection of a variety of genetic alterations, including more focal ABCB1 amplification as well as the other putative biomarkers KDM5D deletion and ERG-TMPRSS2 translocation, even in cfDNA samples with tumor purity <7%. The gene discussed is ABCB1; the disease is neoplasm.